1. Introduction {#sec1}
===============

Basal cell carcinoma (BCC) is currently the most frequent single cancer type in individuals of European ancestry worldwide and a tumor that preferentially affects older males within the 6^th^ to 8^th^ decades of life \[[@B1]\]. The reasons why this cancer, being more frequent for females among individuals younger than about 40 years becomes later in life a disease with distinct androtropy are still elusive. Herein, in order to examine the increment kinetics of BCC incidence as a function of age, studies reporting age-specific incidence rates were identified from the literature and the patterns of age-dependency of age-specific BCC incidence rates between females and males were compared.

2. Material and Methods {#sec2}
=======================

Based on a PubMed literature search (February 15, 2018) from the initially 1151 papers localized with the search string "\[(basal cell carcinoma) OR (skin cancer)\] AND (age-specific incidence)" 181 studies reporting sex-stratified, age-specific incidence rates (*R*) of BCC were identified according to abstract content for full-text evaluation. The criteria for the final selection step of the studies to be included in the analysis are compiled in [Table 1](#tab1){ref-type="table"}. To ensure sufficient number of age classes ("age-sensitivity") only papers reporting BCC data in age classes ≤10 years and at least 2 age classes for patients younger than 40 years were included. Only papers were considered that presented data in Table form. In order to have sufficient cases representation in all age classes only those studies were considered that reported ≥250 disease cases (either "numbers of patients" or "numbers of tumors"). To balance for a confounding phototype effect, only studies reporting data from European countries or populations of European descent were included ([Table 1](#tab1){ref-type="table"}). Finally, studies reporting either data of selected age ranges or certain anatomical locations, e.g. the nose, were excluded. Each reported *R*-value was assigned to the median of the corresponding age span. For the same age class of each study male to female *R* ratios (RR) were calculated and were assigned to the corresponding median age. Using sex ratios of BCC incidence rates for of each age class and each publication separately is anticipated to ameliorate possible genetic (and phototype) variability between the reference populations of the different studies (this approach is further commented in \[[@B2]\]). Approximate standard errors of RR were calculated based on the available sex-stratified "case numbers". Employing SPSS (Chicago, IL, USA) age trends were assessed with Kendall\'s *τ* test and relationships between two variables by inverse variance-weighed Loess and linear regression analysis. Statistical significance was indicated by *P* value \<0.05 (two-sided).

3. Results {#sec3}
==========

Sixteen data sets (published between 1988 and 2014) were eligible ([Table 2](#tab2){ref-type="table"}). In parallel to the known increase of *R* with age for both sexes (not shown), we confirmed a significant shift in the male to female ratio of the age-specific incidence rates as a function of age (Kendall\'s *τ* = 0.530; *P* \< 0.001; [Figure 1](#fig1){ref-type="fig"}). For persons younger than \~45--50 years, *R* is lower and for those \>50 years higher for males (significantly higher in the ages 60--80 years). [Figure 2](#fig2){ref-type="fig"} displays dyads of related male vs. female age-specific BCC incidence rates (same data set, same age). The slope parameter of the best fit (*r*^2^ = 0.980) regression line *b* = 1.205 (standard error: SE = 0.014) predicts a statistically significant about 20% faster *R* increment in males (*P* = 0.001). Notably the relationship of the increase rates of *R* between the two sexes seems to be constant and independent of age. In addition, the value of this increment is not significantly affected by the different coding of BCC cases in the different studies ([Table 2](#tab2){ref-type="table"}; *P* = 0.074 for the comparison "number of patients" vs. "numbers of cases").

4. Discussion {#sec4}
=============

Age and sex are two major, nonmodifiable factors of the risk of an individual to be diagnosed with cancer \[[@B3]\]and together these two factors significantly modulate the incidence of the disease at the population level: Cancer is a disease of aging \[[@B4]\] and taking all age groups together a disease that is more frequent in males than in females; however, not in all ages \[[@B2], [@B5]\]. The well-known higher sum cancer incidence of males as a whole results from the fact that cancer is more frequent among males than females in those age groups with the highest disease risk, i.e., elderly people. Our present data compilation suggests that with respect to above epidemiologic characteristics, BCC behaves like an "average cancer", i.e., might serve as a tumor prototype to study above relationships. The age-specific risk of BCC increases steadily with age for both sexes and by several degrees of magnitude from childhood to, at least up, to the 10^th^ decade of life \[[@B1]\]. In addition, as presently shown, sex substantially modifies the age-specific BCC risk in a dual fashion: At an age around leaving adolescence, females seem to be at a higher risk to develop BCC than males. However, on the other hand, at any age the risk to be diagnosed with BCC (*R*) per unit risk increases as a function of age (*a*) by an excess, but constant and age-independent factor of about 20% (increment factor: 1.205) significantly faster in males (*R*~*M*~) than in females (*R*~*F*~): \[*dR*~*M*~/*da*\]/*R*~*M*~ = 1.205 × \[*dR*~*F*~/*da*\]/*R*~*F*~([Figure 2](#fig2){ref-type="fig"}). This complex age dependence of BCC disease risk results into higher BCC incidence rates for females until the age of about 40--50 years \[[@B6]\]and significantly lower ones in the \>60 years age group (androtropism in the older).

Both biologic and behavioral factors have been proposed to explain above age dependency and sex differences in the incidence rates of cancer (oxidative stress, genome structure and gene expression, immunocompetence, connective tissue stability etc.) \[[@B2]\]. Particularly, the preferential use of tanning beds by younger females than males \[[@B7]\]has been incriminated as an added sex-specific photocarcinogenesis hazard to explain the higher skin cancer incidence of younger females \[[@B8]\]. Our present observation that the BCC risk increases as a function of age more steeply in post-adolescent males of all ages than females cannot be solely explained by differences in the patterns of exposure of the two sexes to skin-specific environmental carcinogens. On the one hand, the constant and independent of age proportionality of the specific BCC risk increment rates between the two sexes is more consistent with the hypothesis of an inherent, biologic factor underlying above relationship. On the other hand, the pattern of higher BCC risk among younger females and at the same time lower among older females compared to males of the same age is not a finding peculiar to this tumor type. Also the age-specific incidence rates of the cutaneous squamous cell carcinoma and of the Merkel cell carcinoma increase as a function of age more abruptly for males compared to females.\[[@B9]\] Even more intriguing, similar sex-characteristic evolution patterns of age specific cancer risk as a function of age are also apparent for the sum of all cancers (excluding keratinocyte skin cancer) in the U.S. population as previously noticed by Cook et al. \[[@B2]\] and is also confirmed by recalculating the last SEER data release (16.3% higher increment rate of the age specific cancer incidence rate of nonhispanic white males \>15 years compared to females, calculated from the SEER Cancer Statistics Review, 1975--2016 data \[[@B10]\]; *p* = 0.959). Similar relationships between the increment rates of age-specific all-cancer incidence rates between males and females are also evident in data from the Australian population,\[[@B11]\] as well as in global compilations of cancer incidence rates (employing the GLOBOCAN data \[[@B12]\] set we calculated a 14.7% higher increment rate of the age-specific cancer incidence rate of males \>15 years compared to females; *p* = 0.978). It is worth noting that sex seems to be an inherent, biologic feature of the mechanism that underlies fixing and accumulation of mutations in human cancers. In parallel to presently discussed differences in the modes of the increase of the age-specific incidence rates as a function of age the number of mutations per whole exom increases for a series of different nonsex-specific cancers at a significantly higher rate in males compared to females \[[@B13]\]. To our opinion these latter observations are also in line with the recently reviewed evidence that the keratinocyte skin cancer is a marker of a high cancer-risk phenotype \[[@B14]\].

The main limitations of the present study are literature-based design, nonuniform mode of reporting the cases in the included studies and scarcity of data reporting 'extreme\' age groups (patients \<25 and patients \>85 years old). Another limitation is the fusion of data reporting either numbers of patients or tumor in the present compilation. However, as already mentioned, a subgroup analysis of the male vs. female age-specific BCC incidence rates does not reveal significant differences between the two coding types of data report (patients vs. tumors numbers).

Age and sex are two main, nonmodifiable, constitutive factors of BCC susceptibility that interact in a characteristic mode to determine the evolution of BCC disease risk during life. We would like to suggest that because of its high incidence coupled with overall moderate morbidity and extremely low mortality rates \[[@B15]\] BCC may serve as a valuable, single‐tumor paradigm to reproach the complex mechanisms that underlie the interaction of age and sex in the pathogenesis of human malignancies.
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![Male to female ratio of BCC incidence rates as a function of age. Each point represents ratio determination from paired data, i.e., for the same age period within each study. The best fit Loess line is shown (with Epanikov kernel at 50%). It crosses with the RR = 1 line of equal incidence rates of males and females (red line) at the age between 45 and 50 years.](JSC2019-8304271.001){#fig1}

![Age-specific BCC incidence rates (cases/100,000 population) of males as a function of the "twin" female data (same age range, same data set). Black line: best fit regression line (*r*^2^ = 0.980; dashed lines: 95% confidence intervals of predicted value). Red line: line of equal incidence rates of the two sexes (slope: *b*′ = 1.000).](JSC2019-8304271.002){#fig2}

###### 

Criteria for the selection of data sets.

  --------------------------------------------------------------------------------------- -------------------------------------------
  Inclusion criteria                                                                      At least 2 subclasses for ages \<40 years
  Patient / tumor numbers are available in age classes                                    
  Age-specific data for the two sexes separately                                          
  Incidences reported in age intervals ≤10 years                                          
  ≥250 patients/cases included                                                            
  Reference population: Study from a European country or population of European descent   
                                                                                          
  Exclusion criteria                                                                      Restricted to selected age subgroups
  Focus on selected anatomical localizations                                              
  --------------------------------------------------------------------------------------- -------------------------------------------

###### 

Compilation of included data sets.

  Data set   PMID       First author \[^a^\]          Publication year   Country       Follow up period   Coding     Age range^b^      Age classes   Age class mode^c^
  ---------- ---------- ----------------------------- ------------------ ------------- ------------------ ---------- ----------------- ------------- -------------------
  1          7547221    Levi \[[@B16]\]               1988               Switzerland   1976--1985         Patient    (30--34)-(85+)    5 yr          N0--N4
  2          2322501    Roberts \[[@B17]\]            1990               UK            1988               Patient    (25--29)-(85+)    5 yr          N0--N4
  3          2312827    Chuang \[[@B18]\]             1990               USA           1976--1984         Patient    (0--14)-(85+)     10 yr         N5--\[N+1\]4
  4          1954125    Coebergh \[[@B19]\]           1991               Netherlands   1975--1988         Patient    (0--14)-(85+)     5 yr          N0--N4
  5          1985867    Magnus \[[@B20]\]             1991               Norway        1976--1982         Neoplasm   (−19)-(90+)       10 yr         N0--N9
  6          11122025   Holme \[[@B21]\]              2000               UK            1998               Patient    (25--29)-(85+)    5 yr          N0--N4
  7          11568742   Harris \[[@B22]\]             2001               USA           1985--1996         Patient    (\<20)-(\>80)     10 yr         N0--N9
  8          14578155   Athas \[[@B23]\]              2003               USA           1977--1978         Neoplasm   (25--34)-(75+)    10 yr         N5--\[N+1\]4
  9          14578155   Athas \[[@B23]\]              2003               USA           1998--1999         Neoplasm   (25--34)-(75+)    10 yr         N5--\[N+1\]4
  10         14520447   Stang \[[@B24]\]              2003               Germany       1995--1999         Patient    (30--34)-(85+)    5 yr          N0--N4
  11         17640064   Bath-Hextall \[[@B25]\]       2007               UK            1996--2003         Patient    (18--24)-(80+)    5 yr          N0--N4
  12         17550552   Stang \[[@B26]\]              2007               Germany       1998--2003         Patient    (10--19)-(\>80)   10 yr         N0--N9
  13         18649084   Radespiel-Tröger \[[@B27]\]   2008               Germany       2001--2005         Patient    (0--29)-(80+)     10 yr         N0--N9
  14         19796178   Bielsa \[[@B28]\]             2009               Spain         2006--2007         Neoplasm   (0--4)-(85+)      5 yr          N0--N4
  15         19595266   Celic \[[@B29]\]              2009               Croatia       2003--2005         Neoplasm   (0--9)-(80+)      10 yr         N0--N9
  16         24874476   Reinau \[[@B30]\]             2014               UK            2000--2011         Patient    (18--19)-(80+)    5 yr          N0--N4

^a^Reference number. ^b^Younger and oldest age group considered. ^c^*N*  = integer 0--9; for example for *N* = 4: N0--N9 corresponds to 40--49 and N5--\[N+1\]4 to 45--54.
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